- $19.98m
- $10.71m
- $57.57m
Aytu BioPharma Q4 revenue beats analyst estimates on EXXUA sales
Aytu Biopharma Inc expected to post a loss of 32 cents a share - Earnings Preview
Aytu BioPharma Q3 revenue falls amid EXXUA launch
Aytu BioPharma Q2 revenue beats expectations
Aytu BioPharma Q1 revenue beats expectations
Aytu BioPharma Q4 revenue misses estimates
Aytu Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Aytu Biopharma Inc expected to post a loss of 17 cents a share - Earnings Preview
Aytu Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview
Aytu Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Aytu Biopharma Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Aytu Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Aytu Biopharma Inc expected to post a loss of 64 cents a share - Earnings Preview
Aytu Biopharma Inc expected to post a loss of 64 cents a share - Earnings Preview
Aytu Biopharma Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Aytu Biopharma Says Entered Deal With Halo Pharmaceutical On Nov 13